Spanish pharma company making injectable drugs (heparins) and providing fill-finish manufacturing, including for Moderna's vaccines.
Spanish pharma company making injectable drugs (heparins) and providing fill-finish manufacturing, including for Moderna's vaccines.
Pays its way from heparin sales plus contract manufacturing for other companies' injectables, Moderna among them. Its long-acting risperidone technology is licensed to Teva, which sells it in the US as Uzedy, so Rovi receives royalties and milestones rather than product sales. The López-Belmonte family controls the company.
In one line: A smaller Catalent/injectable-drug specialist.
Moat: narrow (process know-how, regulatory licence, customer qualification). Sterile-injectable and fill-finish expertise plus regulatory approvals are hard to replicate quickly.
Headquarters: Madrid, Spain · Founded: 1946 · Employees: 2,232
Size Laboratorios Farmaceuticos Rovi (ROVI.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $3.75B, the 32nd largest of 93 Spain companies the cockpit tracks. Shares closed at €67.60 on 18 Nov 2026.
Performance Over six months the shares gained 12.3%, against +1.6% for the median peer and +5.3% for the Spain market (cap-weighted) — 7th highest of 19 in its peer set.
Growth Revenue grew 14.4% over the last twelve months (peer median +8.4%); the operating margin is 20.2% (peer median 15.7%).
Valuation It trades at 21.9× forward earnings against a peer median of 19.9× (6th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.1 points above its cost of capital (5.7% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €829M | €743M | €764M | €830M | €818M |
| Revenue growth | — | -3% | -8% | +1% | — |
| Gross profit | €524M | €452M | €450M | €464M | €497M |
| EBITDA | €204M | €204M | €207M | €244M | €277M |
| Net income | €206M | €140M | €137M | €170M | €200M |
| Free cash flow | €119M | €120M | €77.5M | €60.6M | €187M |
| Capital expenditure | €79.7M | €67.8M | €62.2M | €55.2M | €51.4M |
| Total debt | €101M | €137M | €126M | €65.4M | €72.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Laboratorios Farmaceuticos Rovi ROVI.MC | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Gerresheimer GXI.DE | $1.26B | +21% | +9% | -4% | 16.0× | 57.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% |
| Lonza LONN.SW | $53.9B | +36% | -11% | 25% | 36.1× | 15.6% |
| Siegfried SFZN.SW | $3.51B | -17% | +4% | 16% | 16.8× | n/a |
| Samsung Biologics 207940.KS | $48.7B | -6% | -20% | 43% | 34.4× | 7.0% |
| Fresenius SE & Co. KGaA FRE.DE | $32.7B | +41% | +7% | 10% | 14.7× | 7.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ROVI.MC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.2% | -0.2% | 5th highest of 21 |
| 6-month return | +12.3% | +1.6% | 7th highest of 19 |
| Distance from 52-week high | -22.0% | -29.5% | 9th highest of 21 |
| Revenue growth (TTM) | +14.4% | +8.4% | 7th highest of 18 |
| Operating margin | 20.2% | 15.7% | 5th highest of 17 |
| Forward P/E | 21.9× | 19.9× | 6th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 1.2% | 5.5% | 6th least demanding of 13 |
| Growth delivered (Del g) | +12.1% | +6.7% | 4th highest of 13 |
| Hurdle (Req g minus delivered) | -10.9 pp | -7.7 pp | 7th least demanding of 13 |
| ROIC minus cost of capital | +9.1 pp | +4.3 pp | 6th highest of 18 |
| EV / EBITDA | 17.0× | 25.3× | 5th cheapest of 10 |
| Net debt / EBITDA | 0.1× | 0.2× | 5th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |